Dariohealth Corp - DRIO STOCK NEWS

DarioHealth Corp. (Nasdaq: DRIO) has secured its first government contract with a Midwestern city to provide digital therapeutic solutions addressing chronic conditions for several thousand city employees. The contract, set to commence in Q1 2023, aims to enhance employee health in diabetes, hypertension, weight management, and behavioral health. This partnership expands Dario's employer footprint, supporting the City’s employee health strategy while aiming for better health outcomes at lower costs.

DarioHealth Corp. (NASDAQ: DRIO) presented new research at the IASP 2022 World Congress on Pain, highlighting the effectiveness of its biofeedback posture trainer in reducing back pain. The study, involving nearly 1,000 participants, found a direct correlation between increased usage of the device and improved posture, leading to reduced pain levels. Dr. Yifat Hershcovitz emphasized the importance of user engagement in achieving positive outcomes. This research furthers Dario's commitment to understanding the mechanisms of clinical improvement in their digital therapeutic solutions.

DarioHealth Corp. (Nasdaq: DRIO) reported a Q2 2022 revenue of $6.2 million, marking a 17.5% increase from Q2 2021. The six-month revenue reached $14.2 million, a 60.8% increase. Key developments include a new contract with a national health plan, projected to add nearly 10 million members. The company reported a net loss of $18 million for Q2 2022, with an operating loss of $17.4 million. Operating expenses decreased by 5.2% year-over-year. Dario continues to transition to its B2B2C focus while maintaining a strong pipeline for future growth.

DarioHealth Corp. (Nasdaq: DRIO) announced new research demonstrating that its digital health solutions effectively improve glycemic control in rural residents with Type 2 diabetes, similar to outcomes seen in urban populations. The study, presented at the ADCES Annual Conference, revealed significant reductions in average blood glucose levels over 12 months for both groups. This suggests that Dario's platform can address healthcare challenges faced by rural communities, potentially enhancing access to effective chronic condition management.

DarioHealth Corp. (NASDAQ: DRIO) will announce its financial results for Q2 2022 on August 15, 2022, at 8:30 am ET. The announcement will be followed by a conference call hosted by CEO Erez Raphael, President Rick Anderson, and CFO Zvi Ben-David. Participants should dial in 10 minutes early to the numbers provided. A replay will be available shortly after the event until September 15, 2022. DarioHealth provides digital health solutions for chronic conditions, aiming to enhance patient management through personalized interventions and data analytics.

DarioHealth Corp. (Nasdaq: DRIO) presented new research at the American Psychological Association Annual Convention on August 4-6, 2022, highlighting its digital behavioral health solution's effectiveness. Findings revealed that 72% of users with clinically elevated depression symptoms saw a reduction over 12 weeks, while 44% experienced significant improvements. Additionally, 68% of users with moderate to severe anxiety reported improvements, with 40% achieving clinically significant reductions. The studies emphasize Dario's integrated approach, associating better health outcomes for individuals with chronic conditions.